Related Experiment Video
Updated: May 28, 2025

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
The ZNF717-rs2918520 genotype contributes to COVID-19 severity: a Taiwanese cohort study
Yang-Hsiang Lin1, Jen Yu2, Yu-Chuan Teng3
1Liver Research Center, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Insights
A novel single nucleotide polymorphism (SNP), ZNF717-rs2918520, was identified in Taiwanese COVID-19 patients. The GG genotype of this SNP is significantly associated with severe COVID-19 symptoms, potentially serving as a severity predictor.
Area of Science:
- Genetics and genomics
- Infectious diseases
- Clinical diagnostics
Background:
- Coronavirus disease 2019 (COVID-19) poses a global health challenge, particularly severe respiratory failure.
- Single nucleotide polymorphisms (SNPs) are crucial genetic markers for disease prediction and prognosis.
- Understanding genetic predispositions is vital for managing COVID-19 severity.
Purpose of the Study:
- To investigate the clinical associations of SNPs with mild and severe COVID-19 symptoms in the Taiwanese population.
- To identify potential genetic predictors for COVID-19 severity.
Main Methods:
- Two independent cohorts of SARS-CoV-2 infected patients were enrolled (n=39 and n=71).
- Clinical data and genetic information were analyzed using whole exome sequencing, polymerase chain reaction, and Sanger sequencing.
- Associations between clinical parameters and SNP genotypes with COVID-19 severity were evaluated.
Main Results:
- Clinical factors like age, liver enzymes, and inflammatory markers correlated with COVID-19 severity.
- A novel SNP, ZNF717-rs2918520, was identified.
- The GG genotype of ZNF717-rs2918520 showed a significant association with severe COVID-19 symptoms.
Conclusions:
- The ZNF717-rs2918520 GG genotype may serve as a valuable predictor for COVID-19 severity in Taiwan.
- This finding contributes to personalized medicine approaches for managing COVID-19.
Background:
Coronavirus disease 2019 (COVID-19) has been a challenging pandemic since late 2019 and patients with COVID-19-related severe respiratory failure associated with high mortality rates worldwide. Genetic information such as single nucleotide polymorphisms (SNPs) serves as a predictor or prognostic factor in disease development and cancer progression. This study aimed to explore the clinical associations of SNPs with mild and severe COVID-19 symptoms in the Taiwanese population.
Methods:
SARS-CoV-2-infected patients in pilot cohort study (cohort 1, n = 39) and validation cohort (cohort 2, n = 71) were enrolled. The clinical significance of SNPs in those patients with mild and severe symptoms was investigated by whole exon sequencing, polymerase chain reaction and Sanger sequencing.
Results:
The current study investigated Taiwanese patients with COVID-19. We found that clinical parameters such as age, aspartate aminotransferase, blood urea nitrogen, C-reactive protein, ferritin, and segment were positively associated with severe COVID-19 symptoms but that albumin, lymphocytes, and basophils correlated negatively with severe symptoms in two independent cohorts. By conducting whole-exome sequencing, we identified a novel SNP, ZNF717-rs2918520, the GG genotype of which was significantly associated with severe symptoms in COVID-19 patients.
Conclusions:
Our findings highlight that the ZNF717-rs2918520 GG genotype may serve as a predictor for evaluating the severity of COVID-19 in Taiwan.
Related Concept Videos
Single Nucleotide Polymorphisms-SNPs
Viral Mutations
Pleiotropy
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Viral Recombination

